17-α,21-Dihydroxypregna-4,9(11)-dien-3,20-dion-21-acetat Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Anecortave acetate, an angiogenesis inhibitor, was launched
in Australia by Alcon for the treatment of age-related
macular degeneration (AMD). AMD is the leading cause of
untreatable blindness among people aged 65 to 74 years in
the U.S. Worldwide, approximately 20 to 25 million people suffer from AMD, a disease that until recently was untreatable.
Anecortave, an angiostatic steroid, down-regulates the
expression MMP-2 and -9 to exert its antiangiogenic effects.
Chemische Eigenschaften
Off-White Solid
Verwenden
As an angiostatic steroid, Anecortave Acetate can be used in treatment of macular degeneration.
Enzyminhibitor
This novel angiogenesis pro-drug (FW = 386.48 g/mol; CAS 7753-60-8) is taken up and metabolically de-esterified to form the aqnecortave, a synthetic steroid that suppresses the development and elongation of neovascular sprouts and tip cell motility in a VEGF-treated retinal explant model in a dose-dependent manner. Whether used as monotherapy or in combination with sub-therapeutic doses of cisplatin, anecortave acetate significantly controlled tumor burden in a murine retinoblastoma model.
17-α,21-Dihydroxypregna-4,9(11)-dien-3,20-dion-21-acetat Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
